Drug intelligence / Profile preview

dexamethasone + docetaxel

Development stage: Unknown
Lead developer: Sanofi
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

A combination therapy where dexamethasone is used as a premedication for docetaxel administration to prevent hypersensitivity reactions and fluid retention. Docetaxel is a semisynthetic microtubule inhibitor that arrests the cell cycle and causes apoptosis, while dexamethasone is a corticosteroid that helps reduce adverse reactions to docetaxel.

Targets

TUBB (Tubulin (alpha and beta subunits))GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on dexamethasone + docetaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dexamethasone + docetaxel.

Explore the full profile